全文获取类型
收费全文 | 39篇 |
免费 | 6篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 1篇 |
口腔科学 | 2篇 |
临床医学 | 11篇 |
内科学 | 13篇 |
皮肤病学 | 2篇 |
神经病学 | 2篇 |
特种医学 | 1篇 |
外科学 | 6篇 |
预防医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 3篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2018年 | 1篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 1篇 |
2014年 | 4篇 |
2013年 | 7篇 |
2012年 | 1篇 |
2010年 | 3篇 |
2009年 | 2篇 |
2006年 | 1篇 |
2005年 | 1篇 |
2003年 | 1篇 |
2001年 | 1篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 4篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1969年 | 1篇 |
1963年 | 1篇 |
排序方式: 共有46条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
Congenital nasal neuroglial heterotopia and encephaloceles: An update on current evaluation and management
下载免费PDF全文
![点击此处可从《The Laryngoscope》网站下载免费的PDF全文](/ch/ext_images/free.gif)
15.
Linda McKie BA MSc Phd Mazen Al-Bashir MB Bch MSc MRCGP Tanya Anagnostopoulou BA MA MA Phd Peter Csepe MD Helena Fonseca MD Aida El-Asfahani BSc MSc PhD Stanislav Funiak MD PhD Rachel Javetz BA MA PhD Samsu Samsuridjal MD 《Journal of advanced nursing》1993,18(12):1911-1916
This paper presents the deliberations and conclusions of an international group of health practitioners, researchers and planners who met in 1991 to explore risky behaviours and risk assessment in the context of the World Health Organization's strategy Health for All By 2000 A definition of risky behaviours is discussed and a method of exploring risk contexts,'a risk equation', is presented Lay risk assessment is explored and contrasted with professional perceptions of risk as evidenced in health education campaigns It is concluded that the application of epidemiological techniques — the study of the incidence and prevalence of risk-related and health-related behaviours — employing qualitative methods provides a useful means of exploring the social and cultural context of risk behaviour 相似文献
16.
17.
Mansoor R. Mirza MD Antonio González-Martín MD PhD Whitney S. Graybill MD David M. O’Malley MD Lydia Gaba MD Oi Wah Stephanie Yap MD Eva M. Guerra MD Peter G. Rose MD Jean-François Baurain MD PhD Sharad A. Ghamande MD MBBS Hannelore Denys MD PhD Emily Prendergast MD Carmela Pisano MD Philippe Follana MD Klaus Baumann MD Paula M. Calvert MB Bch BAO Jacob Korach MD Yong Li PhD Izabela A. Malinowska MD PhD Divya Gupta MD Bradley J. Monk MD 《Cancer》2023,129(12):1846-1855
Background
The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.Methods
In the phase 3 PRIMA trial, patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy (N = 733) were initially treated with a fixed starting dose (FSD) regimen of 300 mg once daily. Subsequently, the protocol was amended so newly enrolled patients received an ISD: 200 mg once daily in patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL, and 300 mg once daily in all other patients. Efficacy and safety outcomes were assessed by starting dose.Results
Overall, 475 (64.8%) patients were assigned to an FSD (niraparib, n = 317; placebo, n = 158) and 258 (35.2%) were assigned to an ISD (niraparib, n = 170; placebo, n = 88). Efficacy in patients who received FSD or ISD was similar for the overall (FSD hazard ratio [HR], 0.59 [95% CI, 0.46–0.76] vs. ISD HR, 0.69 [95% CI, 0.48–0.98]) and the homologous recombination–deficient (FSD HR, 0.44 [95% CI, 0.30–0.64] vs. ISD HR, 0.39 [95% CI, 0.22–0.72]) populations. In patients with low body weight/platelet count, rates of grades ≥3 and 4 hematologic treatment-emergent adverse events, dose interruptions, and dose reductions were lower for those who received ISD than for those who received FSD.Conclusions
In PRIMA, similar dose intensity, similar efficacy, and improved safety were observed with the ISD compared with the FSD regimen. 相似文献18.
19.